While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more
Global Market Comments
March 15, 2019
Fiat Lux
Featured Trade:
(BUY JOHNSON & JOHNSON ON THE BAD NEWS),
(JNJ), ($INDU), (PFE), (NVS), (AZN)
When one of the 30 Dow Average companies ($INDU) gets into trouble, I sit up and take note, stand to attention and drill down with a magnifying glass.
After all, it may have a major important on an important tradable index, thus opening up an investment opportunity. It also may sound the alarm for a great single stock pick. That is certainly the case with New Brunswick, NJ based Johnson & Johnson, one of the oldest companies traded on the NYSE.
What piqued my interest today was the news that the company lost another talcum power lawsuit, which is alleged by plaintiffs to contain asbestos. This has been among the catalog of urban conspiracies for decades now.
Johnson & Johnson (JNJ) is, in fact, carrying on with their mission to strengthen their pharma sector which has consistently served as their top revenue driver in the past years. While their strong performance in this segment has always been led by their oncology portfolio, with sales of their cancer drugs increasing by 22.1% worldwide in the previous quarter, it looks like more and more products are on their way to becoming JNJ's blockbuster items.
The company estimates to launch more than ten new drugs -- all of which have the potential to be blockbuster products -- by 2021. On top of these, JNJ expects to complete 50 line extensions on their existing products. Both efforts are anticipated to temper the effects of generic drugs that are threatening to hamper the sales of a lot of key products in JNJ's portfolio.
The latest potential blockbuster drug for JNJ is Esketamine which is an anti-depressant aimed at treatment-resistant patients. This was developed by the company’s pharmaceutical arm, Janssen Pharmaceuticals Inc. This new groundbreaking product was approved on March 5 by the FDA and will be marketed as Spravato. It is hailed as the first prescription depression drug developed from ketamine, which is more commonly used as an anesthetic.
Although ketamine has long been tagged as a party drug, aka “Special K”, and is approved as an anesthetic, no company has patented its use. This is where Janssen swooped in and patented the left section of the molecule, called esketamine, and sent their application to FDA. The approval of this drug, which FDA described as a “breakthrough therapy” thus receiving priority review, translates to a potential cash cow for JNJ as it successfully legitimized the application of ketamine as an anti-depression drug.
Aside from depression, FDA is also taking into consideration the applicability of esketamine to patients afflicted with mood disorders such as bipolar disorder. The organization looks at it as a potential solution for reducing suicides as well.
Other drugs projected to rake in massive sales for JNJ pipeline include psoriatic arthritis Tremfya, prostate cancer medication Erleada, and metastatic urothelial cancer treatment Erdafitinib. With the addition of Spravato on the list, sales are expected to reach more than $1 billion.
However, no company is perfect and the same goes for products -- even if they are poised to become blockbuster drugs. A major hindrance for the success of Spravato is cost.
Here's a sample quote for potential patients.
A one-month initial treatment will cost somewhere from $4,000 to $7,000. The exact price will depend on the dosage and if it's availed wholesale. Expenses for follow-up treatments will reach $2,360 to $3,500 a month. All in all, Spravato could become as expensive as an electroconvulsive treatment or even a transcranial magnetic stimulation therapy. Worse, this treatment might have to be shouldered by the patients themselves.
Another deterrent for investors looking into JNJ is the continuing issue concerning the talcum powder lawsuits which claim that the talc items of the company contain asbestos that resulted in ovarian cancer among many of its female users. As of August 2018, a Missouri court has ordered JNJ to pay 22 women a total of $4.7 billion for damages. While the company announced its decision to appeal the ruling, the case has been a huge red flag for investors ever since.
Nonetheless, it appears that JNJ remains a solid stock for a lot of investors.
With an annual revenue of $81.6 billion, (JNJ) is anticipated to stay ahead of its competitors Pfizer (PFE) ($53.4B), Novartis (NVS) ($51B), and AstraZeneca (AZN) ($21.9B). Taking into consideration currency impact, which is expected to negatively affect sales by roughly 1.5%, JNJ's revenues are projected to hit $80.4 to $81.2 billion this year.
While it still has a long way to go, the recent approval of Spravato spelled higher confidence in JNJ's revenue growth this year. The company's purchase of robotic surgical instruments manufacturer Auris Health, for $3.4 billion further strengthened its dominance in the industry.
In the past month alone, its shares rose by 4.55%. Investors are also anticipating more growth until the next earnings report, which is anticipated to show $2.10 earnings per share for the company. This represents a 1.49% year-over-year increase.
A Killer?
“The bubble is in the bond market, not the stock market” said Leon Cooperman, CEO of Omega Advisors, an original investor in my 1990’s hedge fund.
Mad Hedge Hot Tips
March 14, 2019
Fiat Lux
The Five Most Important Things That Happened Today
(and what to do about them)
1) Boeing Hits Bottom, as the US becomes the last country to ban the 737 Max 8. Imagine being 35,000 feet in the air and you find out your plane is grounded for safety reasons, as 6,000 people did yesterday. Buy more (BA) on the dip. The next move is from $360 to $450. Click here.
2) New Homes Sales Down 6.9%, in January, far worse than expected. The report is an unmitigated disaster for the industry. If you’re trying to sell a house now, you’re screwed. Click here.
3) Weekly Jobless Claims Jump, by 6,000 to a seasonally adjusted 229,000. Notice claims aren’t calling anymore. Another sign the tax cut stimulus is shrinking? Click here.
4) The Number of US Millionaires Grew for the 10th Year, to 11.8 million. And some 1.4 million are worth $5 million to $25 million. You’re obviously not working hard enough. Click here.
5) General Electric to Burn $2 billion This Year, but the stock rallies anyway. We may be trying to put in a long term bottom this year. Buy (GE) on the dips. Click here.
Published today in the Mad Hedge Global Trading Dispatch and Mad Hedge Technology Letter:
(LEARN MORE ABOUT ME THAN YOU PROBABLY WANT TO KNOW),
(GOOG), (AMZN), (AMGN)
(AIRBNB’S SECOND THOUGHTS),
(AIRBNB)
While the Diary of a Mad Hedge Fund Trader focuses on investment over a one week to a six-month time frame, Mad Day Trader, provided by Bill Davis, will exploit money-making opportunities over a brief ten minute to three-day window. It is ideally suited for day traders, but can also be used by long-term investors to improve market timing for entry and exit points. Read more
Mad Hedge Technology Letter
March 14, 2019
Fiat Lux
Featured Trade:
(AIRBNB’S SECOND THOUGHTS),
(AIRBNB)
In an unusual U-turn, Airbnb co-founder Nathan Blecharczyk revealed sudden skepticism on his companies’ odds of going public in 2019.
The base case was that Airbnb was on schedule to be listed in mid-2019.
Blecharczyk fueled confusion by going on record saying that Airbnb “are taking the steps to be ready to go public in 2019. That doesn’t mean we will go public in 2019.”
The company is currently valued at $31 billion.
The co-founder resisted in offering a specific explanation in why the company is hesitant in pulling back from the public market, but part of the factors could boil down to the Brexit mess currently ongoing at 10 Downing Street and the trade war between America and China creating uncertainty around crucial Airbnb housing markets.
Executing the IPO is another quandary where the Securities and Exchange Commission (SEC) shuttered its IPO division during the government shutdown and its staff has not regained full capabilities.
The global economic slowdown has made IPO investors nervous and the slew of IPOs planned for 2019 could take rolling rain checks to ensure the stability of newly minted shares.
This is not the only problem roiling Airbnb.
Taxes.
Municipalities are sick of being shafted from the outsized revenues pocketed by Airbnb.
Hotels have been incessantly complaining that they are on the leash for taxes that Airbnb does not have to face even though they are directly competing.
Things are about to change.
Let’s take the state of Maryland as an example.
Hosts are now pre-warning potential guests that they are on the hook for 15.5% in taxes upon arrival.
The sticker shock could have the effect of killing demand or reducing it severely.
Another bill before the Senate Budget and Taxation Committee would force short-term rental brokers to collect the 6% Maryland sales and use tax at the time of booking and pass on the fees to the state.
And this is just the beginning when you consider the onslaught of regulation other states are grappling with.
Take for instance, Maryland’s neighbor Washington D.C.
The capital has come down heavy-handed on the short-term rental platform forbidding property owners renting out 2nd homes.
They have also limited the days owners can rent out their house if they are not currently present in the city forcing owners to stick around to maximize revenue.
As of now, D.C. taxes Airbnb and other short-term rental companies 14.5% and the company has aired its grievances claiming favoritism towards the local hotel industry.
City councilors have cited figures as much as $96 million over four years of potential lost taxes.
Airbnb has been painted as the scapegoat by many jurisdictions around America when you consider that traditional hotels are taxed at 13% if averaged out in the largest 150 cities.
In many cases, Airbnb is treated not as a hotel and is responsible to self-report its occupancy and revenue data giving them a chance to find loopholes to push large amounts of revenue streams through unscathed.
Governments are also dealing with additional headaches of a wave of displacement for regular payroll jobs because of the domination of Airbnb units.
This whole situation will go from bad to worse because local government is frothing at the mouth when they understand the potential tax windfall they could seize from these online platforms.
Whether legitimate or not, states could cite taxes on hotels as a starting point and start purging Airbnb of revenue through cumbersome charges, fees, licenses, penalties, and regulation.
Airbnb could end up with a bunch of Miami Beach markets on their books with the situation on the ground turning into a slugfest.
The state is at war with property owners who rent out their unit short-term with owners trying to skirt the law.
Any rentals of less than 6 months have been illegal in Miami for years.
Fines were small amounts just three years ago but the tsunami of demand to rent units at tourist hot-spots has ignited the debate of short-term rentals and the pros and cons to business and the community.
The fines have exploded to $20,000 for each citation and the local government has bombarded owners with over $8 million in fines since 2016.
Complicating the matter, owners are often not even the culprits renting out the units.
Tenants who sign up for legitimate leases are running the show themselves muddying the situation in who is liable for the fine – the owner or the tenant?
Short-term rentals have generated over $10 million in taxes to Miami-Dade County in 2018, but the state is continuing to take the stance that this tax would have flooded their coffers plus more from hotels.
This sets up a dire situation in which Airbnb will need to report quarterly earnings 4 times per year and explain to analysts and investors alike the state of regulations and engagement with authorities.
I believe the situation will deteriorate with both sides entrenching more looking to get what they want potentially turning into a legal circus.
Tech firms are known to play hardball and brinkmanship encourages rapid growth, however, this will be harder as a public company.
Airbnb is on the way to ex-growth as mounting financial and regulatory burdens are engulfing the firm.
Better to get their ducks all in a row and supercharge growth one last time before the founders finally get their big payday.
Delaying the IPO is a risky move, but if they can squeeze out a few local victories from a New York, London, or another high market revenue driver and the fact they have been cash flow positive for the last few years, look for them to rush into the IPO and cash out.
And when that time comes, Airbnb’s ultimate competitive advantage of paying minimal taxes in many locales could be dead and buried and the company might become a shell of its former self.
I’ve seen crazier things happen.
YOU ARE FINED $20,000
“When you offer consumers choice, let them vote with their wallets.” - Said Co-Founder of Airbnb Nathan Blecharczyk
Global Market Comments
March 14, 2019
Fiat Lux
Featured Trade:
(LEARN MORE ABOUT ME THAN YOU PROBABLY WANT TO KNOW),
(GOOG), (AMZN), (AMGN)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.